News | July 21, 2025
Aarti Drugs posts Q1 FY26 PAT higher at Rs. 54 Cr
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
This facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms
The UK authorization is based on positive results from the Phase III OASIS-1, -2, and -3 trials
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
Talicia is also approved and launched in the UAE and additional countries may accept UK MHRA approvals as a reference for their own marketing approval processes
Alkem Medtech to acquire 100% stake of Bombay Ortho
The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K.
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
Glenmark’s consolidated revenue was at Rs. 3,387.6 crore as against Rs. 2,506.7 crore recording an increase of 35.1% YoY
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
